Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Epiceram Experts for Eczema: Dermatologists

Council Members in this Study Group: 12

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Sunil Dhawan, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITYSunil Dhawan

Clinical Assistant Professor of Dermatology
STANFORD UNIVERSITY
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed...

Brian Lester

Dermatologist
Brian W Lester, MD
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Brian Lester, MD, is a Dermatologist in private practice in Massachusetts. His interests include clinical dermatology, cosmetic dermatology, dermatopathology, and dermatologic pharmaceuticals. He has experience with clinical trials involving a variety...

Michele Pauporte, Dermatologist, JUVA SKIN LASER CENTER INCMichele Pauporte

Dermatologist
JUVA SKIN LASER CENTER INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michele Pauporte, MD, is a dermatologist at Juva Skin and Laser Center, in New York City. Dr. Pauporte's areas of expertise include cosmetic procedures and the treatment of skin cancers, including Mohs micrographic surgery and reconstructive surgery....

Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTERJeffrey Weinberg

Director of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTER
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Jeffrey Weinberg, MD, is Director of the Clinical Research Center in the Department of Dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, both of which are part of the Continuum Health Partners hospital system in New York....

Alan Fleischer

Professor and Chair of Dermatology
Wake Forest University School of Medicine - CC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alan Fleischer, MD, is a Professor and Chair of Dermatology at the Wake Forest University School of Medicine. In addition to his general and surgical dermatology practice, he has been the primary investigator on dozens of Phase II through Phase IV clinical...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Peplin merger with Leo pharma

November 19, 2009

Leo Pharma completes merger pact with Peplin | www.pharmabiz.com

The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.

Presta Trial shows good results for Enbrel

October 14, 2009

New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com

This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy, and more convenient dosing regimens. Both will be doing similar studies.

Starpharma gets US patent for use of VivaGel for protection against STIs

September 29, 2009

Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com

Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves from infection with genital herpes and HIV during sex. Surveys show that there is substantial demand in North America and Europe for such a product with an estimated billion dollar market for STI prevention products in the developed world.

Stelara new Option for Psoriasis

September 26, 2009

Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com

The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability to fight infections, the product poses a risk of infection. "Serious infections have been reported in patients receiving the product and some of them have led to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer," the FDA states.

Probiotics and Atopic Dermatitis

April 27, 2009

Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. | www.ncbi.nlm.nih.gov

Large, well-conducted meta-analysis shows as a preventative strategy, probiotics may have a modest effect on decreasing the incidence of atopic eczema. However, in terms of treating active disease or preventing recurrence of disease, no convincing evidence supports the use of the probiotics examined thus far.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Owner
  • President
  • Physician - Director
  • Physician - Department Chair

GLG Live Meetings with this Study Group's Leading Experts (?)

January 25, 2008 | Boston

GLGi: Psoriasis and Medical Dermatology

GLG Webcasts & Teleconferences

Leading Experts in Epiceram Experts for Eczema: Dermatologists have not participated in any GLG webcasts.

View All GLG Webcasts & Teleconferences in Healthcare